Palbociclib Intermedia CAS 1016636-76-2 Puritas >99.0% (HPLC) Factory

Description:

Nomen chemicum: 6-bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H)-one

CAS: 1016636-76-2

Puritas: >99.0% (HPLC)

Aspectus: Alba et lux Yellow pulveris

Medium Palbociclib (CAS: 571190-30-2)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Ruifu Chemical Supple Palbociclib Intermedia:
Palbociclib CAS 571190-30-2
5-Bromo-2,4-Dichloropyrimidines CAS 36082-50-5
5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine CAS 733039-20-8
tert-Butyl 4-(6-Nitropyridin-3-yl) piperazine-1-Carboxylate CAS 571189-16-7
tert-Butyl 4-(6-Amino-3-pyridyl) piperazine-1-Carboxylate CAS 571188-59-5
6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H)-one CAS 1016636-76-2
2-Chloro-8-Cyclopentyl-5-Methyl-8H-pyrido[2,3-d]pyrimidin-7-one CAS 1013916-37-4

Chemical Properties:

Nomen chemicum	6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H)-unus
Synonyma	Palbociclib-Pb3
CAS Number	1016636-76-2
CATTUS Number	RF-PI1849
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C13H13BrClN3O
M. Pondus	342.63
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba ad lux Yellow pulveris
Puritas / Analysis Methodus	>99.0% (HPLC)
Substantiae cognatae	<1.00%
Damnum in Siccatio	<0.50%
Aquae (KF)	<0.50%
Test Standard	Enterprise Standard
Consuetudinem	Medium Palbociclib (CAS: 571190-30-2)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

FAQ:

Applicatio:

6-Bromo-2-chloro-8-cyclopentyl-5-methylpyrido-[2,3-d]pyrimidin-7(8H)-unum (CAS: 1016636-76-2) medium est Palbociclib (CAS: 571190- 30-2).Palbociclib medicamentum est ad curationem carcinomatis ER-positivi et HER2-negativi carcinomatis effecti.Palbociclib inhibitor selectivorum cyclini-dependens kinases CDK4 et CDK6 est.Die 3 Februarii 2015, US FDA approbavit Pfizer Palbociclib (nomen artis Ibrance) ad curationem cancri pectoris metastatici in feminis postmenopausalibus.Palbociclib est primus CDK4/6 inhibitor ad recipiendum FDA approbationem.